Dustin B Stephens1, April M Young2, Jennifer R Havens3. 1. University of Kentucky College of Medicine, Department of Behavioral Science, 845 Angliana Ave., Lexington, KY 40508, USA. Electronic address: dbst222@g.uky.edu. 2. University of Kentucky College of Public Health, Department of Epidemiology, 111 Washington Avenue, Office 211C, Lexington, KY 40536, USA; University of Kentucky College of Medicine, Department of Behavioral Science, Center on Drug and Alcohol Research, 845 Angliana Ave., Lexington, KY 40508, USA. Electronic address: april.young@uky.edu. 3. University of Kentucky College of Medicine, Department of Behavioral Science, Center on Drug and Alcohol Research, 845 Angliana Ave., Lexington, KY 40508, USA. Electronic address: jhave2@uky.edu.
Abstract
BACKGROUND: Hepatitis C virus (HCV) remains a major contributor to morbidity and mortality worldwide. Since 2009, Kentucky has led the United States in cases of acute HCV, driven largely by injection drug use in rural areas. Improved treatment regimens hold promise of mitigating the impact and transmission of HCV, but numerous barriers obstruct people who inject drugs (PWID) from receiving care, particularly in medically underserved settings. METHODS: 503 rural people who use drugs were recruited using respondent-driven sampling and received HCV screening and post-test counseling. Presence of HCV antibodies was assessed using enzyme immunoassay of dried blood samples. Sociodemographic and behavioral data were collected using computer-based questionnaires. Predictors of contacting a healthcare provider for follow-up following HCV-positive serotest and counseling were determined using discrete-time survival analysis. RESULTS: 150 (59%) of 254 participants reported contacting a healthcare provider within 18 months of positive serotest and counseling; the highest probability occurred within six months of serotesting. 35 participants (14%) reported they were seeking treatment, and 21 (8%) reported receiving treatment. In multivariate time-dependent modeling, health insurance, internet access, prior substance use treatment, meeting DSM-IV criteria for generalized anxiety disorder, and recent marijuana use increased the odds of making contact for follow-up. Participants meeting criteria for major depressive disorder and reporting prior methadone use, whether legal or illegal, were less likely to contact a provider. CONCLUSION: While only 8% received treatment after HCV-positive screening, contacting a healthcare provider was frequent in this sample of rural PWID, suggesting that the major barriers to care are likely further downstream. These findings offer insight into the determinants of engaging the cascade of medical treatment for HCV and ultimately, treatment-as-prevention. Further study and increased resources to support integrated interventions with effectiveness in other settings are recommended to mitigate the impact of HCV in this resource-deprived setting.
BACKGROUND:Hepatitis C virus (HCV) remains a major contributor to morbidity and mortality worldwide. Since 2009, Kentucky has led the United States in cases of acute HCV, driven largely by injection drug use in rural areas. Improved treatment regimens hold promise of mitigating the impact and transmission of HCV, but numerous barriers obstruct people who inject drugs (PWID) from receiving care, particularly in medically underserved settings. METHODS: 503 rural people who use drugs were recruited using respondent-driven sampling and received HCV screening and post-test counseling. Presence of HCV antibodies was assessed using enzyme immunoassay of dried blood samples. Sociodemographic and behavioral data were collected using computer-based questionnaires. Predictors of contacting a healthcare provider for follow-up following HCV-positive serotest and counseling were determined using discrete-time survival analysis. RESULTS: 150 (59%) of 254 participants reported contacting a healthcare provider within 18 months of positive serotest and counseling; the highest probability occurred within six months of serotesting. 35 participants (14%) reported they were seeking treatment, and 21 (8%) reported receiving treatment. In multivariate time-dependent modeling, health insurance, internet access, prior substance use treatment, meeting DSM-IV criteria for generalized anxiety disorder, and recent marijuana use increased the odds of making contact for follow-up. Participants meeting criteria for major depressive disorder and reporting prior methadone use, whether legal or illegal, were less likely to contact a provider. CONCLUSION: While only 8% received treatment after HCV-positive screening, contacting a healthcare provider was frequent in this sample of rural PWID, suggesting that the major barriers to care are likely further downstream. These findings offer insight into the determinants of engaging the cascade of medical treatment for HCV and ultimately, treatment-as-prevention. Further study and increased resources to support integrated interventions with effectiveness in other settings are recommended to mitigate the impact of HCV in this resource-deprived setting.
Authors: Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt Journal: Lancet Date: 2011-07-27 Impact factor: 79.321
Authors: Jason Grebely; Elizabeth Knight; Krista A Genoway; Mark Viljoen; Milan Khara; Doug Elliott; Lesley Gallagher; Michelle Storms; Jesse D Raffa; Stanley DeVlaming; Fiona Duncan; Brian Conway Journal: Eur J Gastroenterol Hepatol Date: 2010-03 Impact factor: 2.566
Authors: Jennifer R Havens; Michelle R Lofwall; Simon D W Frost; Carrie B Oser; Carl G Leukefeld; Richard A Crosby Journal: Am J Public Health Date: 2012-11-15 Impact factor: 9.308
Authors: Shruti H Mehta; Becky L Genberg; Jacquie Astemborski; Ravi Kavasery; Gregory D Kirk; David Vlahov; Steffanie A Strathdee; David L Thomas Journal: J Community Health Date: 2008-06
Authors: Jason Grebely; Krista Genoway; Milan Khara; Fiona Duncan; Mark Viljoen; Doug Elliott; Jesse D Raffa; Stanley DeVlaming; Brian Conway Journal: Int J Drug Policy Date: 2007-04-27
Authors: Asher J Schranz; Jessica Barrett; Christopher B Hurt; Carlos Malvestutto; William C Miller Journal: Curr HIV/AIDS Rep Date: 2018-06 Impact factor: 5.071
Authors: Rebecca Bolinski; Kaitlin Ellis; Whitney E Zahnd; Suzan Walters; Colleen McLuckie; John Schneider; Christofer Rodriguez; Jerel Ezell; Samuel R Friedman; Mai Pho; Wiley D Jenkins Journal: Transl Behav Med Date: 2019-11-25 Impact factor: 3.046
Authors: Donna M Evon; Christopher B Hurt; Delesha M Carpenter; Sarah K Rhea; Caitlin M Hennessy; William A Zule Journal: Rural Ment Health Date: 2022-02-03
Authors: Adam Baus; Andrea Calkins; Judith Feinberg; Kim McManaway; Susan Moser; Cecil Pollard; Richard Sutphin Journal: Perspect Health Inf Manag Date: 2022-01-01
Authors: Jennifer R Havens; Takako Schaninger; Hannah Fraser; Michelle Lofwall; Michele Staton; April M Young; Ardis Hoven; Sharon L Walsh; Peter Vickerman Journal: BMJ Open Date: 2021-07-05 Impact factor: 2.692